Risk factors for long-term prognosis in hepatocellular carcinoma after radiofrequency ablation therapy: The clinical implication of aspartate aminotransferase-platelet ratio index

European Journal of Gastroenterology and Hepatology

Volumn 23, Issue 6, 2011, Pages 528-536

  Kao, Wei Yu ^a   Chiou, Yi You ^a,b   Hung, Hung Hsu ^a,b   Chou, Yi Hong ^a,b   Su, Chien Wei ^a,b,c   Wu, Jaw Ching ^a,c   Huo, Teh Ia ^a,d   Huang, Yi Hsiang ^a,c   Lin, Han Chieh ^a,b   Lee, Shou Dong ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b Faculty of Medicine   (Taiwan)

^c Institute of Clinical Medicine   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Aspartate aminotransferase to platelet ratio index; hepatocellular carcinoma; prognosis; radiofrequency ablation; recurrence

Indexed keywords

ASPARTATE AMINOTRANSFERASE;

AGE DISTRIBUTION; AGED; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER MORTALITY; CANCER RECURRENCE; HUMAN; LIVER CELL CARCINOMA; LONG TERM CARE; MAJOR CLINICAL STUDY; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTHROMBIN TIME; RADIOFREQUENCY ABLATION; RISK FACTOR; THROMBOCYTE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHI-SQUARE DISTRIBUTION; CLINICAL ENZYME TESTS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TAIWAN; TIME FACTORS; TREATMENT OUTCOME;

EID: 79955571589     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328346d529     Document Type: Article

References (44)

1. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008; 48 (Suppl 1):S20-S37
2. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42:1208-1236 (Pubitemid 43112690)
3. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010; 52:762-773
4. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010; 4:439-474
5. Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005; 129:122-130 (Pubitemid 41002049)
6. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005; 54:1151-1156
7. Lopez PM, Villanueva A, Llovet JM. Systematic review: Evidence-based management of hepatocellular carcinoma - an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 2006; 23:1535-1547 (Pubitemid 43727460)
8. Sutherland LM,Williams JA, Padbury RT, Gotley DC, Stokes B, Maddern GJ. Radiofrequency ablation of liver tumors: A systematic review. Arch Surg 2006; 141:181-190 (Pubitemid 43276571)
9. Garrean S, Hering J, Saied A, Helton WS, Espat NJ. Radiofrequency ablation of primary and metastatic liver tumors: A critical review of the literature. Am J Surg 2008; 195:508-520 (Pubitemid 351417476)
10. Hung HH, Chiou YY, Hsia CY, Su CW, Chou YH, Chiang JH, et al. Survival rates are comparable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas. Clin Gastroenterol Hepatol 2011; 9:79-86
11. Huang J, Yan L, Cheng Z, Wu H, Du L, Wang J, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg 2010; 252:903-912
12. Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology 2008; 47:82-89 (Pubitemid 351171044)
13. Hong SN, Lee SY, Choi MS, Lee JH, Koh KC, Paik SW, et al. Comparing the outcomes of radiofrequency ablation and surgery in patients with a single small hepatocellular carcinoma and well-preserved hepatic function. J Clin Gastroenterol 2005; 39:247-252
14. Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006; 243:321-328 (Pubitemid 43327762)
15. Santambrogio R, Opocher E, Zuin M, Selmi C, Bertolini E, Costa M, et al. Surgical resection versus laparoscopic radiofrequency ablation in patients with hepatocellular carcinoma and Child-Pugh class A liver cirrhosis. Ann Surg Oncol 2009; 16:3289-3298
16. Ng KK, Poon RT, Lo CM, Yuen J, Tso WK, Fan ST. Analysis of recurrence pattern and its influence on survival outcome after radiofrequency ablation of hepatocellular carcinoma. J Gastrointest Surg 2008; 12:183-191
17. Tateishi R, Shiina S, Teratani T, Obi S, Sato S, Koike Y, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma: An analysis of 1000 cases. Cancer 2005; 103:1201-1209 (Pubitemid 40328091)
18. Nouso K, Matsumoto E, Kobayashi Y, Nakamura S, Tanaka H, Osawa T, et al. Risk factors for local and distant recurrence of hepatocellular carcinomas after local ablation therapies. J Gastroenterol Hepatol 2008; 23:453-458 (Pubitemid 351342067)
19. N'Kontchou G, Mahamoudi A, Aout M, Ganne-Carrie N, Grando V, Coderc E, et al. Radiofrequency ablation of hepatocellular carcinoma: Long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology 2009; 50:1475-1483
20. Huo TI, Huang YH, Su CW, Lin HC, Chiang JH, Chiou YY, et al. Validation of the HCC-MELD for dropout probability in patients with small hepatocellular carcinoma undergoing locoregional therapy. Clin Transplant 2008; 22:469-475
21. Tsai MC, Wang JH, Hung CH, Kee KM, Yen YH, Lee CM, et al. Favorable alpha-fetoprotein decrease as a prognostic surrogate in patients with hepatocellular carcinoma after radiofrequency ablation. J Gastroenterol Hepatol 2010; 25:605-612
22. Wu JC, Huang YH, Chau GY, Su CW, Lai CR, Lee PC, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol 2009; 51:890-897
23. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003; 38:200-207 (Pubitemid 36169630)
24. Hung HH, Su CW, Lai CR, Chau GY, Chan CC, Huang YH, et al. Fibrosis and AST to platelet ratio index predict post-operative prognosis for solitary small hepatitis B-related hepatocellular carcinoma. Hepatol Int 2010; 4:691-699
25. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128:343-350 (Pubitemid 40439195)
26. Kim SU, Ahn SH, Park JY, Kang W, Kim do Y, Park YN, et al. Liver stiffness measurement in combination with noninvasive markers for the improved diagnosis of B-viral liver cirrhosis. J Clin Gastroenterol 2009; 43:267-271
27. Shiha G, Sarin SK, Ibrahim AE, Omata M, Kumar A, Lesmana LA, et al. Liver fibrosis: Consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Hepatol Int 2009; 3:323-333
28. Su CW, Chan CC, Hung HH, Huo TI, Huang YH, Li CP, et al. Predictive value of aspartate aminotransferase to alanine aminotransferase ratio for hepatic fibrosis and clinical adverse outcomes in patients with primary biliary cirrhosis. J Clin Gastroenterol 2009; 43:876-883
29. Nunes D, Fleming C, Offner G, Craven D, Fix O, Heeren T, et al. Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastroenterol 2010; 105:1346-1353
30. Couinaud C. Liver anatomy: Portal (and suprahepatic) or biliary segmentation. Dig Surg 1999; 16:459-467 (Pubitemid 30072153)
31. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35:421-430 (Pubitemid 32844200)
32. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2008 update. Hepatol Int 2008; 2:263-283
33. Lam VW, Ng KK, Chok KS, Cheung TT, Yuen J, Tung H, et al. Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma. J Am Coll Surg 2008; 207:20-29
34. Choi D, Lim HK, Rhim H, Kim YS, Lee WJ, Paik SW, et al. Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a firstline treatment: Long-term results and prognostic factors in a large singleinstitution series. Eur Radiol 2007; 17:684-692
35. Lencioni R, Cioni D, Crocetti L, Franchini C, Pina CD, Lera J, et al. Earlystage hepatocellular carcinoma in patients with cirrhosis: Long-term results of percutaneous image-guided radiofrequency ablation. Radiology 2005; 234:961-967 (Pubitemid 40250844)
36. Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006; 44:1543-1554 (Pubitemid 44970357)
37. Breitenstein S, Dimitroulis D, Petrowsky H, Puhan MA, Mullhaupt B, Clavien PA. Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg 2009; 96:975-981
38. Lencioni RA, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L, et al. Small hepatocellular carcinoma in cirrhosis: Randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003; 228:235-240 (Pubitemid 36736097)
39. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Ierace T, Solbiati L, et al. Hepatocellular carcinoma: Radio-frequency ablation of medium and large lesions. Radiology 2000; 214:761-768 (Pubitemid 30115377)
40. Komorizono Y, Oketani M, Sako K, Yamasaki N, Shibatou T, Maeda M, et al. Risk factors for local recurrence of small hepatocellular carcinoma tumors after a single session, single application of percutaneous radiofrequency ablation. Cancer 2003; 97:1253-1262 (Pubitemid 36237312)
41. Pawlik TM, Delman KA, Vauthey JN, Nagorney DM, Ng IO, Ikai I, et al. Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 2005; 11:1086-1092 (Pubitemid 41341758)
42. Nathan H, Schulick RD, Choti MA, Pawlik TM. Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg 2009; 249:799-805
43. Chen CH, Chang TT, Cheng KS, Su WW, Yang SS, Lin HH, et al. Do young hepatocellular carcinoma patients have worse prognosis? The paradox of age as a prognostic factor in the survival of hepatocellular carcinoma patients. Liver Int 2006; 26:766-773 (Pubitemid 44165243)
44. Saneto H, Kobayashi M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, et al. Clinicopathological features, background liver disease, and survival analysis of HCV-positive patients with hepatocellular carcinoma: Differences between young and elderly patients. J Gastroenterol 2008; 43:975-981.